Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Income Statement [Abstract]
Revenue	$ 0	$ 0	$ 0	$ 0
Operating expenses:
Research and development	3,722	22	10,926	2,019
General and administrative	2,349	1,955	11,389	6,027
Restructuring and other costs	0	6	0	940
Total operating expenses	6,071	1,983	22,315	8,986
Loss from operations	(6,071)	(1,983)	(22,315)	(8,986)
Other income, net	224	156	413	593
Net loss	$ (5,847)	$ (1,827)	$ (21,902)	$ (8,393)
Net loss per share - basic	$ (0.27)	$ (0.4)	$ (1.31)	$ (1.85)
Net loss per share - diluted	$ (0.27)	$ (0.4)	$ (1.31)	$ (1.85)
Weighted average common shares outstanding - basic	21,663,089	4,541,167	16,687,473	4,541,167
Weighted average common shares outstanding - diluted	21,663,089	4,541,167	16,687,473	4,541,167
Comprehensive loss:
Net loss	$ (5,847)	$ (1,827)	$ (21,902)	$ (8,393)
Other comprehensive gain:
Unrealized (loss) gain on investments, net of tax of $0	(4)	2	37	48
Total other comprehensive (loss) gain	(4)	2	37	48
Total comprehensive loss	$ (5,851)	$ (1,825)	$ (21,865)	$ (8,345)